79. Homozygous familial hypercholesterolemia
128 clinical trials,   105 drugs   (DrugBank: 29 drugs),   8 drug target genes,   15 drug target pathways

Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-004856-68-NO
(EUCTR)
29/04/201526/01/2015A 12-week, open-label , all subjects will first receive 2 weeks of placebo drug and then active medication in a dose escalating manner: each patient will first receive 50 mg, after evaluation the option exists to increase the dose to to 100 mg and after another evaluation to 200 mg active study drug, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH)A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH) Homozygous Familial Hypercholesterolemia;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: MBX-8025
Product Code: MBX-8025
INN or Proposed INN: MBX-8025
CymaBay Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
8Phase 2France;Netherlands;Norway
2EUCTR2014-004856-68-NL
(EUCTR)
23/04/201528/01/2015A 12-week, open-label , all subjects will first receive 2 weeks of placebo drug and then active medication in a dose escalating manner: each patient will first receive 50 mg, after evaluation the option exists to increase the dose to to 100 mg and after another evaluation to 200 mg active study drug, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH)A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH) Homozygous Familial Hypercholesterolemia;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: MBX-8025
Product Code: MBX-8025
INN or Proposed INN: MBX-8025
CymaBay Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
8Phase 2France;Norway;Netherlands
3NCT02472535
(ClinicalTrials.gov)
April 201522/5/2015Study to Evaluate the Effects of MBX-8025 in Patients With HoFHA 12-week, Open-label, Dose-escalating, Phase 2 Study to Evaluate the Effects of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)Homozygous Familial HypercholesterolemiaOther: Run-In Period: Placebo;Drug: MBX-8025 50 mg (Dose Escalation Period 1);Drug: MBX-8025 50 mg or 100 mg (Dose Escalation Period 2);Drug: MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)CymaBay Therapeutics, Inc.NULLCompleted18 YearsN/ABoth13Phase 2Canada;France;Netherlands;Norway
4EUCTR2014-004856-68-FR
(EUCTR)
13/03/201519/05/2015A 12-week, open-label , all subjects will first receive 2 weeks of placebo drug and then active medication in a dose escalating manner: each patient will first receive 50 mg, after evaluation the option exists to increase the dose to to 100 mg and after another evaluation to 200 mg active study drug, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH)A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH) Homozygous Familial Hypercholesterolemia;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: MBX-8025
Product Code: MBX-8025
INN or Proposed INN: MBX-8025
CymaBay Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
8Phase 2France;Norway;Netherlands